Maine lawmaker wants MaineCare to cover Ozempic and other weight loss drugs
The proposal went before the Health and Human Services Committee for a public hearing on Tuesday.
Ozempic and other similar drugs such as Wegovy and Zepbound can help people lose weight by controlling appetite and reducing cravings.
But the drugs can be pricey, with 30-day prescriptions typically around $1,000 to $1,500. The cost is causing some private insurance to exclude them from coverage in their policies, although that practice has also resulted in lawsuits, including two in Maine.
Despite the cost, the drugs are popular, and according to a 2024 KFF poll, one in eight adult Americans have taken the Ozempic class of medications.
Ozempic and similar drugs were originally approved by the Food and Drug Administration as diabetes medicine, but they have also been found to help control weight. However, of the adults taking the drugs, about 40% are using the medications to treat diabetes, 22% were taking them primarily for weight loss, and the remaining for other reasons.
Anne Graham, D-North Yarmouth, a retired nurse practitioner, and the primary sponsor of the bill, L.D. 480, said MaineCare should cover the popular weight loss medications because patients should have access to all available tools to help them be healthier.
"Everyone should have access to obesity treatment, including these weight loss medications," Graham said.
Thirteen states — including New England states Massachusetts, Connecticut and Rhode Island — have approved the Ozempic class medications for their Medicaid programs. MaineCare is the state's name for Medicaid, which is a federal program operated by the states funded with a mix of federal and state dollars.
Dr. Allen Browne, of Falmouth, a retired pediatric surgeon, testified in favor of the bill, and said it is "wrong" to tell patients that a drug "exists, is safe and effective, but it's not available due to the cost."
Browne said some health care providers will not even mention the weight loss medications to their patients, knowing that it's too pricey for their patients to afford.
But Courtney Pladsen, MaineCare's medical director, testified against the bill, arguing that it would simply be too costly.
"Our conclusion is that the cost of adding this coverage would be prohibitive," said Pladsen, who pointed out that children in the MaineCare program can currently be prescribed Ozempic or similar drugs, but that the drugs are not available in MaineCare to adults.
Pladsen said that adding the medications would cost MaineCare $42 million in 2026 and $53 million in 2027.
"Requiring MaineCare to cover (these drugs) for treating obesity would have a significant fiscal impact. This is untenable given MaineCare's current budget shortfall," Pladsen said.
MaineCare is currently facing an $118 million shortfall in the current fiscal year. Under Gov. Janet Mills' budget proposal, a number of controversial cutbacks would be made to stabilize the MaineCare budget, including eliminating a cost-of-living increase for direct care workers and reductions of stipends for child care workers.
Mills' overall $11.6 billion biennium budget calls for some cutbacks, but also raises revenue with a cigarette tax increase from $1 to $3 per pack, and a 40% increase in the adult use cannabis sales tax, to 14%.
Copy the Story Link
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
CVS Health Corporation (CVS) Is 'The Last Man Standing,' Says Jim Cramer
We recently published . CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is a pharmaceutical retailer whose shares are among the top performers in the industry. They have gained 55% year-to-date and are up by 16.8% since late July. CVS Health Corporation (NYSE:CVS) has performed well on the stock market as its rivals continue to struggle. In his previous remarks about the firm, Cramer has commented on the competitive dynamics and speculated that the stock could go even higher. Here are his latest comments about CVS Health Corporation (NYSE:CVS): '[On a Baird upgrade] I think that they are the last man standing, with Rite Aid pulling back and Walgreen, they're shutting a huge amount of Walgreen since they were sold. I think that by the way, David Joiner, non-promotional. Did a remarkable job in terms of health insurance. They are the one to bet on if you want to be in that area. I don't want to be in that area after reading Semblest let's just put a gun to my head with five bullets I don't want to go there, just bad ratio.' Previously, Cramer discussed CVS Health Corporation (NYSE:CVS)'s stock price: 'Right, and remember, Walgreens shrinkings, Rite-Aid gone away, 185 million people now go to these, including 60 million people who use two or more of their offerings. David, I've got to tell you, they are, if you remember, the one that was the worst, they're now the first. David Joiner, congratulations, you know how to price your business. And, they're getting out of the individual exchange plans in 2026. Goodbye Medicaid? 'Guidance goes, six, six twenty, from five seventy five, six dollars, there's a stock that going to . . .one hundred dollars!' While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Epoch Times
13 hours ago
- Epoch Times
Cataracts: Leading Cause of Blindness—Here Are Its Early Signs
More than 20 million Americans aged 40 and older are affected by cataracts in one or both eyes. By age 75, nearly half of all Americans will develop the condition. Cataracts are a gradual clouding of the eye's natural lens—like looking through a foggy window that slowly becomes more blurred over time. This cloudiness blocks light from reaching the back of the eye, which is why vision becomes less clear.
